- Previous Close
4.0600 - Open
4.1100 - Bid 2.9500 x 100
- Ask 5.0800 x 100
- Day's Range
3.9625 - 4.1100 - 52 Week Range
3.6100 - 20.2100 - Volume
362,268 - Avg. Volume
882,180 - Market Cap (intraday)
144.049M - Beta (5Y Monthly) -0.43
- PE Ratio (TTM)
-- - EPS (TTM)
-4.0100 - Earnings Date Oct 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
28.11
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
biomeafusion.comRecent News: BMEA
View MorePerformance Overview: BMEA
Trailing total returns as of 1/17/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BMEA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BMEA
View MoreValuation Measures
Market Cap
144.05M
Enterprise Value
65.66M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.90
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-56.38%
Return on Equity (ttm)
-104.51%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-144.01M
Diluted EPS (ttm)
-4.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
87.95M
Total Debt/Equity (mrq)
12.59%
Levered Free Cash Flow (ttm)
-65.44M